Ourailidis I, Stogbauer F, Zhou Y, Beck S, Romanovsky E, Eckert S
NPJ Precis Oncol. 2025; 9(1):73.
PMID: 40082664
PMC: 11906922.
DOI: 10.1038/s41698-025-00856-2.
Ren Y, Xiong W, Feng C, Yu D, Wang X, Yang Q
Commun Biol. 2025; 8(1):370.
PMID: 40044946
PMC: 11882983.
DOI: 10.1038/s42003-025-07700-0.
Carmona-Pirez J, Salsoso R, Charpentier E, Olmedo C, Medrano F, Roman L
J Fungi (Basel). 2025; 11(2).
PMID: 39997396
PMC: 11857022.
DOI: 10.3390/jof11020102.
Khayer N, Shabani S, Jalessi M, Joghataei M, Mahjoubi F
Sci Rep. 2025; 15(1):3322.
PMID: 39865116
PMC: 11770085.
DOI: 10.1038/s41598-024-82668-1.
Mohd Faizal N, Shai S, Savaliya B, Karen-Ng L, Kumari R, Kumar R
Biomedicines. 2025; 13(1).
PMID: 39857718
PMC: 11759772.
DOI: 10.3390/biomedicines13010134.
Hallmarks of a genomically distinct subclass of head and neck cancer.
Muijlwijk T, Nauta I, van der Lee A, Grunewald K, Brink A, Ganzevles S
Nat Commun. 2024; 15(1):9060.
PMID: 39428388
PMC: 11491468.
DOI: 10.1038/s41467-024-53390-3.
Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models.
Tsai D, Lovanov A, Abdelmaksoud A, Akhtar J, Dar M, Luff M
iScience. 2024; 27(9):110854.
PMID: 39310755
PMC: 11416682.
DOI: 10.1016/j.isci.2024.110854.
Unveiling the Mechanisms Underlying the Immunotherapeutic Potential of Gene-miRNA and Drugs in Head and Neck Cancer.
Danishuddin , Haque M, Malik M, Arya R, Singh P, Lee J
Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065771
PMC: 11280033.
DOI: 10.3390/ph17070921.
Potential of melatonin to reverse epigenetic aberrations in oral cancer: new findings.
Gil-Martin E, Ramos E, Lopez-Munoz F, Egea J, Romero A
EXCLI J. 2024; 22:1280-1310.
PMID: 38234969
PMC: 10792176.
DOI: 10.17179/excli2023-6624.
Identification of as a Potential Prognostic Marker in Head and Neck Squamous Cell Carcinoma: Analysis.
Wang L, Yin Y, Liu P, Chen H, Xu M
Cancer Genomics Proteomics. 2023; 21(1):41-53.
PMID: 38151293
PMC: 10756347.
DOI: 10.21873/cgp.20428.
Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data.
Zohud O, Lone I, Nashef A, Iraqi F
Animal Model Exp Med. 2023; 6(6):537-558.
PMID: 38129938
PMC: 10757216.
DOI: 10.1002/ame2.12367.
High-Resolution Profiling of Head and Neck Squamous Cells Carcinoma Identifies Specific Biomarkers and Expression Subtypes of Clinically Relevant Vulnerabilities.
Zhu Y, Peng B, Luo X, Sun W, Liu D, Li N
Curr Med Chem. 2023; 31(17):2431-2448.
PMID: 37936459
DOI: 10.2174/0109298673276128231031112655.
Molecular classification of human papilloma virus-negative head and neck squamous cell carcinomas: Cell cycle-based classifier and prognostic signature.
Gu H, Li T, Beeraka N, Zheng Y, Zhang X, Song R
PLoS One. 2023; 18(10):e0286414.
PMID: 37903125
PMC: 10615317.
DOI: 10.1371/journal.pone.0286414.
Construction and validation of a prognostic nine-gene signature associated with radiosensitivity in head and neck squamous cell carcinoma.
Lu C, Sun Q, Guo Y, Han X, Zhang M, Liu J
Clin Transl Radiat Oncol. 2023; 43:100686.
PMID: 37854672
PMC: 10579965.
DOI: 10.1016/j.ctro.2023.100686.
Immune landscape in molecular subtypes of human papillomavirus-negative head and neck cancer.
Xie M, Chaudhary R, Slebos R, Lee K, Song F, Poole M
Mol Carcinog. 2023; 63(1):120-135.
PMID: 37750589
PMC: 10841270.
DOI: 10.1002/mc.23640.
Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response.
Arora R, Cao C, Kumar M, Sinha S, Chanda A, McNeil R
Nat Commun. 2023; 14(1):5029.
PMID: 37596273
PMC: 10439131.
DOI: 10.1038/s41467-023-40271-4.
EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma.
Chaudhary R, Slebos R, Noel L, Song F, Poole M, Hoening D
Cancer Res Commun. 2023; 3(5):896-907.
PMID: 37377902
PMC: 10202124.
DOI: 10.1158/2767-9764.CRC-22-0443.
β-catenin/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer.
Reed E, Jankowski S, Spinella A, Noonan V, Haddad R, Nomoto K
Transl Res. 2023; 260:46-60.
PMID: 37353110
PMC: 10527608.
DOI: 10.1016/j.trsl.2023.05.007.
Plasma metabolomics of oral squamous cell carcinomas based on NMR and MS approaches provides biomarker identification and survival prediction.
Polachini G, de Castro T, Smarra L, Henrique T, de Paula C, Severino P
Sci Rep. 2023; 13(1):8588.
PMID: 37237049
PMC: 10220089.
DOI: 10.1038/s41598-023-34808-2.
Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
Brandt A, Thiele B, Schultheiss C, Daetwyler E, Binder M
Cancers (Basel). 2023; 15(7).
PMID: 37046721
PMC: 10093741.
DOI: 10.3390/cancers15072051.